G1 Therapeutics, Inc. (Nasdaq: GTHX) is a commercial-stage oncology biopharmaceutical company that aims to develop and deliver next-generation therapies that improve the lives of those affected by cancer. The company’s first commercial product, COSELA® (trilaciclib), has been developed and approved for use in the United States. G1 is also currently evaluating therapies in combination with cytotoxic therapies and/or immunotherapy in areas of high unmet need such as triple-negative breast cancer and extensive stage small cell lung cancer.
On Wednesday, May 1, 2024, at 8:30 a.m. ET, G1 Therapeutics will be hosting a webcast and conference call to provide a financial and corporate update for the first quarter of 2024. To register for the event and receive a dial-in number and unique PIN to access the live conference call, please follow the link provided to register online. It is recommended to join 10 minutes prior to the start of the event. A live and archived webcast will be available on the Events & Presentations page of the company’s website at www.g1therapeutics.com. The webcast will be archived on the same page for 90 days following the event.
For further inquiries, individuals can contact Will Roberts, Communications Officer and Vice President of Investor Relations and Corporate Communications at G1 Therapeutics, Inc. He can be reached at (919) 907-1944 or via email at wroberts@g1therapeutics
